Is There a Difference between Ultrasonographic (US) Uterine Changes of Oral Versus Transdermal (TD) 17β Estradiol (17β E2) in Girls with Turner Syndrome (TS)? Own Experience and Literature Review

Jonathan Kraus, Nancy Unanue, Aníbal Espinoza, German Iniguez, Lournaris Torres-Santiago, Ravinder Jit Singh, Nelly Mauras, Veronica Mericq

Research output: Contribution to journalArticle

Abstract

RESULTS: Uterine morphology and endometrial thickness increased comparably in both groups. E2 concentrations were comparable at 12 months between both groups but E1 and E1S were lower in TD group at 12 months.

CONCLUSIONS: According to our experience, in a group of TS patients randomized to oral vs TD 17β E2 and monitored with trans-abdominal US, both groups achieved similar increases in uterine size comparable to normal women. To confirm our observation a larger sample and a longer evaluation period is needed.

BACKGROUND: Among patients with Turner Syndrome (TS), premature ovarian failure is a main feature. Recently published consensus guidelines recommend that transdermal (TD) estradiol is the preferred route for estrogen replacement. Studies related to ultrasound (US) measurements during estrogen replacement in TS patients using estradiol (17β E2) and correlating uterine growth with estrogen metabolites are limited.

OBJECTIVES: To compare uterine morphology and hormonal changes depending on route of administration of 17β E2 (oral vs. TD) in a small population of girls with TS.

SUBJECTS: 11 hypogonadal girls with TS (mean (SE) age 14.5 ± 1.4 years; BMI -0.98 ± -1.0 SDS) who participated in a larger study on the effects of oral versus TD 17β E2 agreed to do a sub-study on the effect of the form of 17β E2 treatment on uterine size.

METHODS: 17β E2 was given orally or TD for 12 months, titrated to doses up to 2 mg orally or 100 μg TD to achieve normal estradiol levels. Subjects received monthly progesterone for 1 week for withdrawal bleeding. At baseline, 6 and 12 months, a pelvic ultrasound was performed while on estradiol only.

Original languageEnglish (US)
Pages (from-to)178-185
Number of pages8
JournalPediatric endocrinology reviews : PER
Volume16
Issue number1
DOIs
StatePublished - Sep 1 2018

Fingerprint

Turner Syndrome
Estradiol
Estrogen Replacement Therapy
Primary Ovarian Insufficiency
Progesterone
Estrogens
Observation
Guidelines
Hemorrhage
Growth
Population

Keywords

  • Estradiol
  • Turner Syndrome
  • Ultrasonography

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Is There a Difference between Ultrasonographic (US) Uterine Changes of Oral Versus Transdermal (TD) 17β Estradiol (17β E2) in Girls with Turner Syndrome (TS)? Own Experience and Literature Review. / Kraus, Jonathan; Unanue, Nancy; Espinoza, Aníbal; Iniguez, German; Torres-Santiago, Lournaris; Singh, Ravinder Jit; Mauras, Nelly; Mericq, Veronica.

In: Pediatric endocrinology reviews : PER, Vol. 16, No. 1, 01.09.2018, p. 178-185.

Research output: Contribution to journalArticle

Kraus, Jonathan ; Unanue, Nancy ; Espinoza, Aníbal ; Iniguez, German ; Torres-Santiago, Lournaris ; Singh, Ravinder Jit ; Mauras, Nelly ; Mericq, Veronica. / Is There a Difference between Ultrasonographic (US) Uterine Changes of Oral Versus Transdermal (TD) 17β Estradiol (17β E2) in Girls with Turner Syndrome (TS)? Own Experience and Literature Review. In: Pediatric endocrinology reviews : PER. 2018 ; Vol. 16, No. 1. pp. 178-185.
@article{6f4b4c1667de4063b2bf0091b7dd3494,
title = "Is There a Difference between Ultrasonographic (US) Uterine Changes of Oral Versus Transdermal (TD) 17β Estradiol (17β E2) in Girls with Turner Syndrome (TS)? Own Experience and Literature Review",
abstract = "RESULTS: Uterine morphology and endometrial thickness increased comparably in both groups. E2 concentrations were comparable at 12 months between both groups but E1 and E1S were lower in TD group at 12 months.CONCLUSIONS: According to our experience, in a group of TS patients randomized to oral vs TD 17β E2 and monitored with trans-abdominal US, both groups achieved similar increases in uterine size comparable to normal women. To confirm our observation a larger sample and a longer evaluation period is needed.BACKGROUND: Among patients with Turner Syndrome (TS), premature ovarian failure is a main feature. Recently published consensus guidelines recommend that transdermal (TD) estradiol is the preferred route for estrogen replacement. Studies related to ultrasound (US) measurements during estrogen replacement in TS patients using estradiol (17β E2) and correlating uterine growth with estrogen metabolites are limited.OBJECTIVES: To compare uterine morphology and hormonal changes depending on route of administration of 17β E2 (oral vs. TD) in a small population of girls with TS.SUBJECTS: 11 hypogonadal girls with TS (mean (SE) age 14.5 ± 1.4 years; BMI -0.98 ± -1.0 SDS) who participated in a larger study on the effects of oral versus TD 17β E2 agreed to do a sub-study on the effect of the form of 17β E2 treatment on uterine size.METHODS: 17β E2 was given orally or TD for 12 months, titrated to doses up to 2 mg orally or 100 μg TD to achieve normal estradiol levels. Subjects received monthly progesterone for 1 week for withdrawal bleeding. At baseline, 6 and 12 months, a pelvic ultrasound was performed while on estradiol only.",
keywords = "Estradiol, Turner Syndrome, Ultrasonography",
author = "Jonathan Kraus and Nancy Unanue and An{\'i}bal Espinoza and German Iniguez and Lournaris Torres-Santiago and Singh, {Ravinder Jit} and Nelly Mauras and Veronica Mericq",
year = "2018",
month = "9",
day = "1",
doi = "10.17458/per.vol16.2018.kue.uschangesversustd",
language = "English (US)",
volume = "16",
pages = "178--185",
journal = "Pediatric endocrinology reviews : PER",
issn = "1565-4753",
publisher = "YS Medical Media Ltd.",
number = "1",

}

TY - JOUR

T1 - Is There a Difference between Ultrasonographic (US) Uterine Changes of Oral Versus Transdermal (TD) 17β Estradiol (17β E2) in Girls with Turner Syndrome (TS)? Own Experience and Literature Review

AU - Kraus, Jonathan

AU - Unanue, Nancy

AU - Espinoza, Aníbal

AU - Iniguez, German

AU - Torres-Santiago, Lournaris

AU - Singh, Ravinder Jit

AU - Mauras, Nelly

AU - Mericq, Veronica

PY - 2018/9/1

Y1 - 2018/9/1

N2 - RESULTS: Uterine morphology and endometrial thickness increased comparably in both groups. E2 concentrations were comparable at 12 months between both groups but E1 and E1S were lower in TD group at 12 months.CONCLUSIONS: According to our experience, in a group of TS patients randomized to oral vs TD 17β E2 and monitored with trans-abdominal US, both groups achieved similar increases in uterine size comparable to normal women. To confirm our observation a larger sample and a longer evaluation period is needed.BACKGROUND: Among patients with Turner Syndrome (TS), premature ovarian failure is a main feature. Recently published consensus guidelines recommend that transdermal (TD) estradiol is the preferred route for estrogen replacement. Studies related to ultrasound (US) measurements during estrogen replacement in TS patients using estradiol (17β E2) and correlating uterine growth with estrogen metabolites are limited.OBJECTIVES: To compare uterine morphology and hormonal changes depending on route of administration of 17β E2 (oral vs. TD) in a small population of girls with TS.SUBJECTS: 11 hypogonadal girls with TS (mean (SE) age 14.5 ± 1.4 years; BMI -0.98 ± -1.0 SDS) who participated in a larger study on the effects of oral versus TD 17β E2 agreed to do a sub-study on the effect of the form of 17β E2 treatment on uterine size.METHODS: 17β E2 was given orally or TD for 12 months, titrated to doses up to 2 mg orally or 100 μg TD to achieve normal estradiol levels. Subjects received monthly progesterone for 1 week for withdrawal bleeding. At baseline, 6 and 12 months, a pelvic ultrasound was performed while on estradiol only.

AB - RESULTS: Uterine morphology and endometrial thickness increased comparably in both groups. E2 concentrations were comparable at 12 months between both groups but E1 and E1S were lower in TD group at 12 months.CONCLUSIONS: According to our experience, in a group of TS patients randomized to oral vs TD 17β E2 and monitored with trans-abdominal US, both groups achieved similar increases in uterine size comparable to normal women. To confirm our observation a larger sample and a longer evaluation period is needed.BACKGROUND: Among patients with Turner Syndrome (TS), premature ovarian failure is a main feature. Recently published consensus guidelines recommend that transdermal (TD) estradiol is the preferred route for estrogen replacement. Studies related to ultrasound (US) measurements during estrogen replacement in TS patients using estradiol (17β E2) and correlating uterine growth with estrogen metabolites are limited.OBJECTIVES: To compare uterine morphology and hormonal changes depending on route of administration of 17β E2 (oral vs. TD) in a small population of girls with TS.SUBJECTS: 11 hypogonadal girls with TS (mean (SE) age 14.5 ± 1.4 years; BMI -0.98 ± -1.0 SDS) who participated in a larger study on the effects of oral versus TD 17β E2 agreed to do a sub-study on the effect of the form of 17β E2 treatment on uterine size.METHODS: 17β E2 was given orally or TD for 12 months, titrated to doses up to 2 mg orally or 100 μg TD to achieve normal estradiol levels. Subjects received monthly progesterone for 1 week for withdrawal bleeding. At baseline, 6 and 12 months, a pelvic ultrasound was performed while on estradiol only.

KW - Estradiol

KW - Turner Syndrome

KW - Ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=85055616283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055616283&partnerID=8YFLogxK

U2 - 10.17458/per.vol16.2018.kue.uschangesversustd

DO - 10.17458/per.vol16.2018.kue.uschangesversustd

M3 - Article

C2 - 30371036

AN - SCOPUS:85055616283

VL - 16

SP - 178

EP - 185

JO - Pediatric endocrinology reviews : PER

JF - Pediatric endocrinology reviews : PER

SN - 1565-4753

IS - 1

ER -